Company news

Myriad Genetics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

September 18, 2023

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

September 17, 2023

New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women

September 5, 2023

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

September 5, 2023

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

September 4, 2023

Myriad Genetics and Onsite Women’s Health Partner to Help More Women Understand Breast Cancer Risk

August 21, 2023

Myriad Genetics to Host Investor Day on September 19, 2023

August 16, 2023

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

August 14, 2023

Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment

August 7, 2023

Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

August 6, 2023

Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth

August 2, 2023

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

July 26, 2023

Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

July 23, 2023

Myriad Genetics Announces New $90 Million Asset-Based Credit Facility

July 5, 2023

Myriad Genetics Announces Research Collaboration to use Minimal Residual Disease Testing Platform

June 11, 2023

Myriad Genetics to Participate in Goldman Sachs Healthcare Conference

June 6, 2023

Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023

May 31, 2023

Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics

May 30, 2023

Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer

May 23, 2023

Myriad Genetics Earns 2023 Great Place to Work Certification™

May 7, 2023

Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range

May 2, 2023

Myriad Genetics to Participate in BofA Securities Healthcare Conference

May 1, 2023

Myriad Genetics to Release First Quarter Financial Results on May 3, 2023

April 25, 2023

77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey

April 18, 2023

Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification

April 17, 2023

Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program

April 11, 2023

Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States

March 1, 2023

Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC

February 28, 2023

Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes

February 27, 2023

Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023

February 21, 2023

Myriad Genetics to Participate in Upcoming Healthcare Conferences

February 8, 2023

Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing

February 6, 2023

Myriad Genetics Applauds New Guidelines Recommending Screening for Chromosomal Abnormalities

January 4, 2023

Myriad Genetics to Present at 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Myriad Genetics Hires Five Senior Leaders to Advance Commercial Growth Plans

December 18, 2022

Myriad Genetics Patient Outcomes Study Shows RiskScore Leads to More Accurate Breast Cancer Risk Prediction than Standard-of-Care Risk Model

December 7, 2022

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Showcasing Advancements in Breast Cancer Risk Assessment and Treatment

November 28, 2022

GeneSight Mental Health Monitor Reveals Gap on the Front Line of Mental Health Care

November 16, 2022

Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting

November 13, 2022

Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information

November 9, 2022

New Study Published in JCO Precision Oncology Features Data Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

November 2, 2022

Myriad Genetics Reports Third Quarter Financial Results

October 31, 2022

Myriad Genetics Expands Consumer Access to Genetic Testing with Acquisition of Gateway Genomics and Its Market-Leading SneakPeek® Early Gender DNA Test

October 31, 2022

Myriad Genetics Expands Board of Directors with Election of Paul M. Bisaro as New Board Member

October 30, 2022

Myriad Genetics to Release Third-Quarter Financial Results on Nov. 1, 2022

October 25, 2022

Family Cancer History Still a Mystery to Many Women, Myriad Genetics Survey Finds

September 27, 2022

New Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients

August 30, 2022

Myriad Genetics Receives Expanded Coverage in Japan for Use of BRACAnalysis® Diagnostic System as a Companion Diagnostic for Lynparza® in Early-Stage Breast Cancer

August 24, 2022

Myriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe

August 15, 2022

Myriad Genetics Reports Second Quarter Financial Results

August 3, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 48 decks. Every deck is listed under its year.